{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:06:07Z","timestamp":1792857967850,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Over the past decade, metabolic dysfunction-associated steatotic liver disease (MASLD) has become a leading cause of chronic liver disease in Japan, with estimated prevalence rising from 33.7% (2020) to 44.8% (2040), owing to an aging population and lean individuals. In this narrative review, we summarize the epidemiology, pathogenesis, diagnostic strategies, and emerging treatments for MASLD and metabolic dysfunction-associated steatohepatitis (MASH) in Japan, culminating in a proposed ideal patient care pathway tailored to local needs. MASLD pathogenesis involves complex interactions between metabolic dysfunction, inflammation, insulin resistance, and genetic susceptibility. In Japan, a stepwise diagnostic algorithm is endorsed, starting with non-invasive liver disease assessments (NILDA) such as fibrosis-4, followed by imaging-based fibrosis evaluation and selective biopsy. We propose a two-tiered diagnosis combining first-line NILDA (fibrosis-4) with second-line NILDA (e.g., enhanced liver fibrosis, Mac-2 binding protein glycosylation isomer, cytokeratin-18 fragment, and\u00a0serum type IV collagen 7S) to refine risk stratification, reduce unnecessary referrals, and optimize healthcare resources, with qualifying patients referred to a hepatologist and treatment plans based on imaging-based NILDA or liver biopsy. The management of MASLD\/MASH relies on lifestyle modification and pharmacological agents targeting metabolic comorbidities. However, novel anti-fibrotic, anti-inflammatory, and metabolism-targeted therapies are advancing, with future treatment decisions expected to integrate genomic and metabolomic profiling alongside NILDA. The proposed care model is multidisciplinary, engaging physicians, hepatologists, dietitians, psychologists, pharmacists, and hepatitis medical care coordinators to address both hepatic and systemic metabolic care. This evolving paradigm emphasizes proactive, personalized care informed by real-world data and long-term monitoring to improve outcomes and quality of life for patients with MASLD\/MASH in Japan.<\/jats:p>","DOI":"10.1007\/s00535-026-02401-9","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:36:51Z","timestamp":1776267411000},"page":"880-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of MASLD\/MASH: challenges, innovations, and the future of patient-centered care in Japan"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3658-5894","authenticated-orcid":false,"given":"Yuya","family":"Seko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-046X","authenticated-orcid":false,"given":"Kanji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"8","key":"2401_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/hepr.14047","volume":"54","author":"H Enomoto","year":"2024","unstructured":"Enomoto H, Akuta N, Hikita H, et al. Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: updated nationwide survey from 2018 to 2021. Hepatol Res. 2024;54(8):763\u201372. https:\/\/doi.org\/10.1111\/hepr.14047.","journal-title":"Hepatol Res"},{"issue":"2","key":"2401_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00535-020-01748-x","volume":"56","author":"H Enomoto","year":"2021","unstructured":"Enomoto H, Ueno Y, Hiasa Y, et al. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol. 2021;56(2):158\u201367. https:\/\/doi.org\/10.1007\/s00535-020-01748-x.","journal-title":"J Gastroenterol"},{"key":"2401_CR3","unstructured":"The Japan Gastroenterological Society. 2023. https:\/\/www.jsge.or.jp\/news\/20231121\/. Accessed June 13, 2025."},{"issue":"5","key":"2401_CR4","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"issue":"6","key":"2401_CR5","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","journal-title":"Hepatology"},{"issue":"2","key":"2401_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12072-021-10143-4","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito T, Ishigami M, Zou B, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995\u20132040. Hepatol Int. 2021;15(2):366\u201379. https:\/\/doi.org\/10.1007\/s12072-021-10143-4.","journal-title":"Hepatol Int"},{"issue":"10","key":"2401_CR7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/hepr.13688","volume":"51","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. Hepatol Res. 2021;51(10):1013\u201325. https:\/\/doi.org\/10.1111\/hepr.13688.","journal-title":"Hepatol Res"},{"issue":"2","key":"2401_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling RK, Duarte-Rojo A, Patel K, et al. AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology. 2025;81(2):672\u2013724. https:\/\/doi.org\/10.1097\/HEP.0000000000000843.","journal-title":"Hepatology"},{"issue":"1","key":"2401_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/HEP.0000000000000845","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling RK, Patel K, Duarte-Rojo A, et al. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology. 2025;81(1):321\u201357. https:\/\/doi.org\/10.1097\/HEP.0000000000000845.","journal-title":"Hepatology"},{"key":"2401_CR10","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis. N Engl J Med. 2025;392:2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"key":"2401_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/nejmoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/nejmoa2309000.","journal-title":"N Engl J Med"},{"issue":"1","key":"2401_CR12","doi-asserted-by":"publisher","first-page":"2445780","DOI":"10.1080\/07853890.2024.2445780","volume":"57","author":"D Wang","year":"2025","unstructured":"Wang D, Miao J, Zhang L, Zhang L. Research advances in the diagnosis and treatment of MASLD\/MASH. Ann Med. 2025;57(1):2445780. https:\/\/doi.org\/10.1080\/07853890.2024.2445780.","journal-title":"Ann Med"},{"issue":"6","key":"2401_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/hepr.14011","volume":"54","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Tamaki N, Kurosaki M, et al. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease. Hepatol Res. 2024;54(6):600\u20135. https:\/\/doi.org\/10.1111\/hepr.14011.","journal-title":"Hepatol Res"},{"issue":"1","key":"2401_CR14","doi-asserted-by":"publisher","first-page":"15442","DOI":"10.1038\/s41598-025-99540-5","volume":"15","author":"C Huang","year":"2025","unstructured":"Huang C, Gao Z, Huang Z, Xu J. Nonlinear association between body roundness index and metabolic dysfunction associated steatotic liver disease in nondiabetic Japanese adults. Sci Rep. 2025;15(1):15442. https:\/\/doi.org\/10.1038\/s41598-025-99540-5.","journal-title":"Sci Rep"},{"issue":"4","key":"2401_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"issue":"1","key":"2401_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"issue":"5","key":"2401_CR17","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389\u201398. https:\/\/doi.org\/10.1016\/S2468-1253(19)30039-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"2401_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S, et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8(1):e2454707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54707.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2401_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/nu16040524","volume":"16","author":"S Sato","year":"2024","unstructured":"Sato S, Chinda D, Iino C, et al. A cohort study of the influence of the 12-component modified Japanese Diet Index on oral and gut microbiota in the Japanese general population. Nutrients. 2024;16(4):524. https:\/\/doi.org\/10.3390\/nu16040524.","journal-title":"Nutrients"},{"issue":"9","key":"2401_CR20","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"2401_CR21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","volume":"56","author":"M Yoneda","year":"2021","unstructured":"Yoneda M, Yamamoto T, Honda Y, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022\u201332. https:\/\/doi.org\/10.1007\/s00535-021-01828-6.","journal-title":"J Gastroenterol"},{"issue":"11","key":"2401_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/hepr.13947","volume":"53","author":"H Fujii","year":"2023","unstructured":"Fujii H, Suzuki Y, Sawada K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: a large-scale multicenter retrospective study. Hepatol Res. 2023;53(11):1059\u201372. https:\/\/doi.org\/10.1111\/hepr.13947.","journal-title":"Hepatol Res"},{"issue":"3","key":"2401_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease \u2013 a global public health perspective. J Hepatol. 2019;70(3):531\u201344. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.033.","journal-title":"J Hepatol"},{"issue":"10","key":"2401_CR24","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.3390\/biomedicines9101346","volume":"9","author":"MS Kuchay","year":"2021","unstructured":"Kuchay MS, Mart\u00ednez-Montoro JI, Choudhary NS, Fern\u00e1ndez-Garc\u00eda JC, Ramos-Molina B. Non-alcoholic fatty liver disease in lean and non-obese individuals: current and future challenges. Biomedicines. 2021;9(10):1346. https:\/\/doi.org\/10.3390\/biomedicines9101346.","journal-title":"Biomedicines"},{"issue":"1","key":"2401_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"2401_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","volume":"91","author":"ZM Younossi","year":"2012","unstructured":"Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91(6):319\u201327. https:\/\/doi.org\/10.1097\/MD.0b013e3182779d49.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"2401_CR27","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/jcm7120562","volume":"7","author":"L Denkmayr","year":"2018","unstructured":"Denkmayr L, Feldman A, Stechemesser L, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med. 2018;7(12):562. https:\/\/doi.org\/10.3390\/jcm7120562.","journal-title":"J Clin Med"},{"issue":"1","key":"2401_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2337\/cd18-0026","volume":"37","author":"P Golabi","year":"2019","unstructured":"Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes. 2019;37(1):65\u201372. https:\/\/doi.org\/10.2337\/cd18-0026.","journal-title":"Clin Diabetes"},{"issue":"1","key":"2401_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.14218\/JCTH.2023.00252","volume":"12","author":"J Tidwell","year":"2024","unstructured":"Tidwell J, Wu GY. Unique genetic features of lean NAFLD: a review of mechanisms and clinical implications. J Clin Transl Hepatol. 2024;12(1):70\u20138. https:\/\/doi.org\/10.14218\/JCTH.2023.00252.","journal-title":"J Clin Transl Hepatol"},{"issue":"10","key":"2401_CR30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/hepr.12648","volume":"46","author":"Y Honda","year":"2016","unstructured":"Honda Y, Yoneda M, Kessoku T, et al. Characteristics of non-obese non-alcoholic fatty liver disease: effect of genetic and environmental factors. Hepatol Res. 2016;46(10):1011\u20138. https:\/\/doi.org\/10.1111\/hepr.12648.","journal-title":"Hepatol Res"},{"issue":"S1","key":"2401_CR31","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/apt.17930","volume":"59","author":"SK Bansal","year":"2024","unstructured":"Bansal SK, Bansal MB. Pathogenesis of MASLD and MASH \u2013 role of insulin resistance and lipotoxicity. Aliment Pharmacol Ther. 2024;59(S1):S10\u201322. https:\/\/doi.org\/10.1111\/apt.17930.","journal-title":"Aliment Pharmacol Ther"},{"key":"2401_CR32","doi-asserted-by":"publisher","first-page":"1433857","DOI":"10.3389\/fcell.2024.1433857","volume":"12","author":"R Sandireddy","year":"2024","unstructured":"Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol. 2024;12:1433857. https:\/\/doi.org\/10.3389\/fcell.2024.1433857.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"2401_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","volume":"56","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56(11):951\u201363. https:\/\/doi.org\/10.1007\/s00535-021-01796-x.","journal-title":"J Gastroenterol"},{"issue":"5","key":"2401_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/jgh3.12367","volume":"4","author":"N Araki","year":"2020","unstructured":"Araki N, Takahashi H, Takamori A, et al. Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non\u2010alcoholic fatty liver disease patients. JGH Open. 2020;4(5):929\u201336. https:\/\/doi.org\/10.1002\/jgh3.12367.","journal-title":"JGH Open"},{"issue":"2","key":"2401_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/cancers16020259","volume":"16","author":"AGS Phoolchund","year":"2024","unstructured":"Phoolchund AGS, Khakoo SI. MASLD and the development of HCC: pathogenesis and therapeutic challenges. Cancers (Basel). 2024;16(2):259. https:\/\/doi.org\/10.3390\/cancers16020259.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2401_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4062\/biomolther.2024.188","volume":"33","author":"H An","year":"2025","unstructured":"An H, Jang Y, Choi J, Hur J, Kim S, Kwon Y. New insights into AMPK, as a potential therapeutic target in metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis. Biomol Ther (Seoul). 2025;33(1):18\u201338. https:\/\/doi.org\/10.4062\/biomolther.2024.188.","journal-title":"Biomol Ther (Seoul)"},{"issue":"1","key":"2401_CR37","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12876-021-02020-z","volume":"21","author":"N Akuta","year":"2021","unstructured":"Akuta N, Kawamura Y, Arase Y, et al. PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD. BMC Gastroenterol. 2021;21(1):434. https:\/\/doi.org\/10.1186\/s12876-021-02020-z.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"2401_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5009\/gnl240407","volume":"19","author":"Y Pei","year":"2025","unstructured":"Pei Y, Goh GBB. Genetic risk factors for metabolic dysfunction-associated steatotic liver disease. Gut Liver. 2025;19(1):8\u201318. https:\/\/doi.org\/10.5009\/gnl240407.","journal-title":"Gut Liver"},{"issue":"12","key":"2401_CR39","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/apt.15738","volume":"51","author":"B Carlsson","year":"2020","unstructured":"Carlsson B, Lind\u00e9n D, Brol\u00e9n G, et al. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020;51(12):1305\u201320. https:\/\/doi.org\/10.1111\/apt.15738.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2401_CR40","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/biomedicines11102761","volume":"11","author":"Y Takahashi","year":"2023","unstructured":"Takahashi Y, Dungubat E, Kusano H, Fukusato T. Pathology and pathogenesis of metabolic dysfunction-associated steatotic liver disease-associated hepatic tumors. Biomedicines. 2023;11(10):2761. https:\/\/doi.org\/10.3390\/biomedicines11102761.","journal-title":"Biomedicines"},{"issue":"7","key":"2401_CR41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00439-013-1294-3","volume":"132","author":"T Kitamoto","year":"2013","unstructured":"Kitamoto T, Kitamoto A, Yoneda M, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2013;132(7):783\u201392. https:\/\/doi.org\/10.1007\/s00439-013-1294-3.","journal-title":"Hum Genet"},{"issue":"7","key":"2401_CR42","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cgh.2024.02.031","volume":"22","author":"Y Seko","year":"2024","unstructured":"Seko Y, Yamaguchi K, Shima T, et al. Differential effects of genetic polymorphism on comorbid disease in metabolic dysfunction\u2013associated steatotic liver disease. Clin Gastroenterol Hepatol. 2024;22(7):1436\u201343.e4. https:\/\/doi.org\/10.1016\/j.cgh.2024.02.031.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2401_CR43","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.3390\/ijms21093089","volume":"21","author":"H Enomoto","year":"2020","unstructured":"Enomoto H, Aizawa N, Hasegawa K, et al. Possible relevance of PNPLA3 and tll1 gene polymorphisms to the efficacy of peg-ifn therapy for HBV-infected patients. Int J Mol Sci. 2020;21(9):3089. https:\/\/doi.org\/10.3390\/ijms21093089.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2401_CR44","doi-asserted-by":"publisher","first-page":"e0185490","DOI":"10.1371\/journal.pone.0185490","volume":"13","author":"T Kawaguchi","year":"2018","unstructured":"Kawaguchi T, Shima T, Mizuno M, et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS ONE. 2018;13(1):e0185490.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0185490.","journal-title":"PLoS ONE"},{"key":"2401_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12944-016-0181-z","volume":"15","author":"S Boonvisut","year":"2016","unstructured":"Boonvisut S, Nakayama K, Makishima S, et al. Replication analysis of genetic association of the NCAN-CILP2 region with plasma lipid levels and non-alcoholic fatty liver disease in Asian and Pacific ethnic groups. Lipids Health Dis. 2016;15:8. https:\/\/doi.org\/10.1186\/s12944-016-0181-z.","journal-title":"Lipids Health Dis"},{"issue":"9","key":"2401_CR46","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.cgh.2013.02.011","volume":"11","author":"R Hernaez","year":"2013","unstructured":"Hernaez R, McLean J, Lazo M, et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the Third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2013;11(9):1183\u201390.e2. https:\/\/doi.org\/10.1016\/j.cgh.2013.02.011.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2401_CR47","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/nejmoa1712191","volume":"378","author":"NS Abul-Husn","year":"2018","unstructured":"Abul-Husn NS, Cheng X, Li AH, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med. 2018;378(12):1096\u2013106. https:\/\/doi.org\/10.1056\/nejmoa1712191.","journal-title":"N Engl J Med"},{"key":"2401_CR48","doi-asserted-by":"publisher","first-page":"e70150","DOI":"10.1002\/jgh3.70150","volume":"9","author":"S Wakabayashi","year":"2025","unstructured":"Wakabayashi S, Kimura T, Tamaki N, et al. AI-based platelet-independent noninvasive test for liver fibrosis in MASLD Patients. JGH Open. 2025; 9:e70150. https:\/\/doi.org\/10.1002\/jgh3.70150.","journal-title":"JGH Open"},{"key":"2401_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.20517\/mtod.2024.44","volume":"4","author":"LM Marks","year":"2024","unstructured":"Marks LM, Jensen T, Degrado TR. Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis. Metab Target Organ Damage. 2024;4:28. https:\/\/doi.org\/10.20517\/mtod.2024.44.","journal-title":"Metab Target Organ Damage"},{"key":"2401_CR50","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.gastha.2024.08.008","volume":"3","author":"M Kawanaka","year":"2024","unstructured":"Kawanaka M, Kamada Y, Takahashi H, et al. Serum cytokeratin 18 fragment is an indicator for treating metabolic dysfunction-associated steatotic liver disease. Gastro Hep Adv. 2024;3:1120\u20138. https:\/\/doi.org\/10.1016\/j.gastha.2024.08.008.","journal-title":"Gastro Hep Adv"},{"key":"2401_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15081023","volume":"15","author":"T Tadokoro","year":"2025","unstructured":"Tadokoro T, Kawanaka M, Takahashi H, et al. A noninvasive method of diagnosing metabolic dysfunction-associated steatohepatitis using cytokeratin-18 fragment and FIB-3 index. Diagnostics Basel. 2025;15:1023. https:\/\/doi.org\/10.3390\/diagnostics15081023.","journal-title":"Diagnostics Basel"},{"issue":"4","key":"2401_CR52","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/1354750X.2018.1425915","volume":"23","author":"T Tada","year":"2018","unstructured":"Tada T, Kumada T, Toyoda H, Saibara T, Ono M, Kage M. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. Biomarkers. 2018;23(4):328\u201334. https:\/\/doi.org\/10.1080\/1354750X.2018.1425915.","journal-title":"Biomarkers"},{"issue":"5","key":"2401_CR53","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1872-034X.2011.00946.x","volume":"42","author":"DJ Leeming","year":"2012","unstructured":"Leeming DJ, Nielsen MJ, Dai Y, et al. Enzyme-linked immunosorbent serum assay specific for the 7S domain of collagen type IV (P4NP 7S): a marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol Res. 2012;42(5):482\u201393. https:\/\/doi.org\/10.1111\/j.1872-034X.2011.00946.x.","journal-title":"Hepatol Res"},{"issue":"1","key":"2401_CR54","doi-asserted-by":"publisher","first-page":"e0563","DOI":"10.1097\/HC9.0000000000000563","volume":"9","author":"H Ishiba","year":"2024","unstructured":"Ishiba H, Fujii H, Kamada Y, et al. Accuracy of type IV collagen 7S versus enhanced liver fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease. Hepatol Commun. 2024;9(1):e0563. https:\/\/doi.org\/10.1097\/HC9.0000000000000563.","journal-title":"Hepatol Commun"},{"key":"2401_CR55","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/hepr.14202","volume":"55","author":"M Kawanaka","year":"2025","unstructured":"Kawanaka M, Fushimi T, Tanikawa T, et al. The new assay type IV collagen 7S (CLEIA) is a useful test to identify progressive fibrosis in chronic liver disease: a study based on magnetic resonance elastography. Hepatol Res. 2025;55:994\u20131004. https:\/\/doi.org\/10.1111\/hepr.14202.","journal-title":"Hepatol Res"},{"issue":"1","key":"2401_CR56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00535-024-02179-8","volume":"60","author":"Y Kamada","year":"2025","unstructured":"Kamada Y, Sumida Y, Takahashi H, Fujii H, Miyoshi E, Nakajima A. Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review. J Gastroenterol. 2025;60(1):10\u201323. https:\/\/doi.org\/10.1007\/s00535-024-02179-8.","journal-title":"J Gastroenterol"},{"key":"2401_CR57","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.17611","volume":"12","author":"S Gong","year":"2024","unstructured":"Gong S, Yu X, Li Q, Chen M, Yu S, Yang S. Evaluation of Mac-2 binding protein glycosylation Isomer (M2BPGi) as a diagnostic marker for staging liver fibrosis: a meta-analysis. PeerJ. 2024;12:e17611. https:\/\/doi.org\/10.7717\/peerj.17611.","journal-title":"PeerJ"},{"issue":"1","key":"2401_CR58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3343\/alm.2021.41.1.16","volume":"41","author":"N Tamaki","year":"2021","unstructured":"Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical utility of Mac-2 binding protein glycosylation isomer in chronic liver diseases. Ann Lab Med. 2021;41(1):16\u201324. https:\/\/doi.org\/10.3343\/alm.2021.41.1.16.","journal-title":"Ann Lab Med"},{"issue":"12","key":"2401_CR59","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s00535-023-02043-1","volume":"58","author":"H Uojima","year":"2023","unstructured":"Uojima H, Nakabayashi K, Yamasaki K, et al. New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation Isomer in chronic liver disease. J Gastroenterol. 2023;58(12):1252\u201360. https:\/\/doi.org\/10.1007\/s00535-023-02043-1.","journal-title":"J Gastroenterol"},{"issue":"7","key":"2401_CR60","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s00535-024-02100-3","volume":"59","author":"H Uojima","year":"2024","unstructured":"Uojima H, Yamasaki K, Sugiyama M, et al. Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation. J Gastroenterol. 2024;59(7):598\u2013608. https:\/\/doi.org\/10.1007\/s00535-024-02100-3.","journal-title":"J Gastroenterol"},{"key":"2401_CR61","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/hepr.13382","volume":"49","author":"Y Honda","year":"2019","unstructured":"Honda Y, Imajo K, Kobayashi T, et al. Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non\u2010alcoholic fatty liver disease. Hepatol Res. 2019;49:1136\u201346. https:\/\/doi.org\/10.1111\/hepr.13382.","journal-title":"Hepatol Res"},{"key":"2401_CR62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s43856-024-00499-7","volume":"4","author":"T Iwadare","year":"2024","unstructured":"Iwadare T, Kimura T, Okumura T, et al. Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease. Commun Med. 2024;4:73. https:\/\/doi.org\/10.1038\/s43856-024-00499-7.","journal-title":"Commun Med"},{"key":"2401_CR63","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/j.1440-1746.2006.04447.x","volume":"21","author":"H Kaneda","year":"2006","unstructured":"Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2006;21:1459\u201365. https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04447.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"2401_CR64","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s00535-023-02038-y","volume":"58","author":"A Kado","year":"2023","unstructured":"Kado A, Tsutsumi T, Yotsuyanagi H, et al. Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern. J Gastroenterol. 2023;58:1237\u201351. https:\/\/doi.org\/10.1007\/s00535-023-02038-y.","journal-title":"J Gastroenterol"},{"issue":"1","key":"2401_CR65","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/diagnostics11010132","volume":"11","author":"K Murayama","year":"2021","unstructured":"Murayama K, Okada M, Tanaka K, et al. Prediction of nonalcoholic fatty liver disease using noninvasive and non-imaging procedures in Japanese health checkup examinees. Diagnostics. 2021;11(1):132. https:\/\/doi.org\/10.3390\/diagnostics11010132.","journal-title":"Diagnostics"},{"issue":"4","key":"2401_CR66","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ21-0563","volume":"69","author":"S Takahashi","year":"2022","unstructured":"Takahashi S, Tanaka M, Higashiura Y, et al. Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population. Endocr J. 2022;69(4):EJ21-0563. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0563.","journal-title":"Endocr J"},{"issue":"4","key":"2401_CR67","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41440-022-01161-2","volume":"46","author":"D Wu","year":"2023","unstructured":"Wu D, Hirata A, Hirata T, et al. Fatty liver index predicts the development of hypertension in a Japanese general population with and without dysglycemia. Hypertens Res. 2023;46(4):879\u201386. https:\/\/doi.org\/10.1038\/s41440-022-01161-2.","journal-title":"Hypertens Res"},{"issue":"2","key":"2401_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/life11020143","volume":"11","author":"Y Sumida","year":"2021","unstructured":"Sumida Y, Yoneda M, Tokushige K, et al. FIB-4 first in the diagnostic algorithm of metabolic-dysfunction- associated fatty liver disease in the era of the global metabodemic. Life. 2021;11(2):1\u201320. https:\/\/doi.org\/10.3390\/life11020143.","journal-title":"Life"},{"issue":"1","key":"2401_CR69","doi-asserted-by":"publisher","first-page":"e0609","DOI":"10.1097\/HC9.0000000000000609","volume":"9","author":"S Sung","year":"2025","unstructured":"Sung S, Al-Karaghouli M, Tam M, et al. Age-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care. Hepatol Commun. 2025;9(1):e0609. https:\/\/doi.org\/10.1097\/HC9.0000000000000609.","journal-title":"Hepatol Commun"},{"issue":"11","key":"2401_CR70","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1007\/s00535-018-1474-y","volume":"53","author":"H Ishiba","year":"2018","unstructured":"Ishiba H, Sumida Y, Tanaka S, et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol. 2018;53(11):1216\u201324. https:\/\/doi.org\/10.1007\/s00535-018-1474-y.","journal-title":"J Gastroenterol"},{"issue":"6","key":"2401_CR71","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/jgh.16144","volume":"38","author":"H Ishiba","year":"2023","unstructured":"Ishiba H, Sumida Y, Kamada Y, et al. Noninvasive tests predict liver\u2010related events and mortality in patients with nonalcoholic fatty liver disease: sub\u2010analysis of the CLIONE\u2010Asia study. J Gastroenterol Hepatol. 2023;38(6):896\u2013904. https:\/\/doi.org\/10.1111\/jgh.16144.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"2401_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108777","volume":"38","author":"SG Albert","year":"2024","unstructured":"Albert SG, Wood EM. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD). J Diabet Complications. 2024;38(7):108777. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108777.","journal-title":"J Diabet Complications"},{"issue":"2","key":"2401_CR73","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","volume":"79","author":"M Kjaergaard","year":"2023","unstructured":"Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79(2):277\u201386. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.002.","journal-title":"J Hepatol"},{"issue":"4","key":"2401_CR74","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/hepr.13871","volume":"53","author":"Y Seko","year":"2023","unstructured":"Seko Y, Takahashi H, Toyoda H, et al. Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: multicenter study. Hepatol Res. 2023;53(4):312\u201321. https:\/\/doi.org\/10.1111\/hepr.13871.","journal-title":"Hepatol Res"},{"issue":"13","key":"2401_CR75","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3390\/diagnostics14131317","volume":"14","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Takaura K, Higuchi M, et al. Enhanced liver fibrosis score for diagnosing liver fibrosis in chronic hepatitis. Diagnostics. 2024;14(13):1317. https:\/\/doi.org\/10.3390\/diagnostics14131317.","journal-title":"Diagnostics"},{"issue":"3","key":"2401_CR76","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12072-022-10454-0","volume":"17","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Shima T, Mitsumoto Y, et al. Fibro-Scope V1.0.1: an artificial intelligence\/neural network system for staging of nonalcoholic steatohepatitis. Hepatol Int. 2023;17(3):573\u201383. https:\/\/doi.org\/10.1007\/s12072-022-10454-0.","journal-title":"Hepatol Int"},{"issue":"2","key":"2401_CR77","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/hepr.14121","volume":"55","author":"Y Seko","year":"2025","unstructured":"Seko Y, Yamaguchi K, Shima T, et al. Prognostic performance of a two\u2010step method using the fibro\u2010scope system for metabolic dysfunction\u2010associated steatotic liver disease. Hepatol Res. 2025;55(2):211\u20138. https:\/\/doi.org\/10.1111\/hepr.14121.","journal-title":"Hepatol Res"},{"issue":"10","key":"2401_CR78","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/hepr.13681","volume":"51","author":"T Okanoue","year":"2021","unstructured":"Okanoue T, Shima T, Mitsumoto Y, et al. Novel artificial intelligent\/neural network system for staging of nonalcoholic steatohepatitis. Hepatol Res. 2021;51(10):1044\u201357. https:\/\/doi.org\/10.1111\/hepr.13681.","journal-title":"Hepatol Res"},{"issue":"3","key":"2401_CR79","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082\u201390. https:\/\/doi.org\/10.1002\/hep.24452.","journal-title":"Hepatology"},{"issue":"2","key":"2401_CR80","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","volume":"19","author":"M Eslam","year":"2025","unstructured":"Eslam M, Fan JG, Yu ML, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025;19(2):261\u2013301. https:\/\/doi.org\/10.1007\/s12072-024-10774-3.","journal-title":"Hepatol Int"},{"issue":"1","key":"2401_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22767-z","volume":"12","author":"T Kobayashi","year":"2022","unstructured":"Kobayashi T, Ogawa Y, Shinoda S, et al. A 3-step approach to predict advanced fibrosis in nonalcoholic fatty liver disease: impact on diagnosis, patient burden, and medical costs. Sci Rep. 2022;12(1):22767-z. https:\/\/doi.org\/10.1038\/s41598-022-22767-z.","journal-title":"Sci Rep"},{"issue":"5","key":"2401_CR82","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE M\u00f3zes","year":"2022","unstructured":"M\u00f3zes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006\u201319. https:\/\/doi.org\/10.1136\/gutjnl-2021-324243.","journal-title":"Gut"},{"key":"2401_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejim.2024.01.013","volume":"122","author":"M Zoncap\u00e8","year":"2024","unstructured":"Zoncap\u00e8 M, Liguori A, Tsochatzis EA. Non-invasive testing and risk-stratification in patients with MASLD. Eur J Intern Med. 2024;122:11\u20139. https:\/\/doi.org\/10.1016\/j.ejim.2024.01.013.","journal-title":"Eur J Intern Med"},{"issue":"7","key":"2401_CR84","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/jgh3.12590","volume":"5","author":"H Fujii","year":"2021","unstructured":"Fujii H, Enomoto M, Fukumoto S, et al. Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. JGH Open. 2021;5(7):801\u20138. https:\/\/doi.org\/10.1002\/jgh3.12590.","journal-title":"JGH Open"},{"issue":"8","key":"2401_CR85","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1055\/a-1666-0431","volume":"130","author":"G Meyer","year":"2022","unstructured":"Meyer G, Dauth N, Grimm M, Herrmann E, Bojunga J, Friedrich-Rust M. Shear wave elastography reveals a high prevalence of NAFLD-related fibrosis even in type 1 diabetes. Exp Clin Endocrinol Diabet. 2022;130(8):532\u20138. https:\/\/doi.org\/10.1055\/a-1666-0431.","journal-title":"Exp Clin Endocrinol Diabet"},{"issue":"4","key":"2401_CR86","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","volume":"75","author":"EA Selvaraj","year":"2021","unstructured":"Selvaraj EA, M\u00f3zes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2021;75(4):770\u201385. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.044.","journal-title":"J Hepatol"},{"key":"2401_CR87","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-024-04546-8","author":"R Yamaguchi","year":"2024","unstructured":"Yamaguchi R, Oda T, Nagashima K. Comparison of the diagnostic accuracy of shear wave elastography with transient elastography in adult nonalcoholic fatty liver disease: a systematic review and network meta-analysis of diagnostic test accuracy. Abdom Radiol. 2024. https:\/\/doi.org\/10.1007\/s00261-024-04546-8.","journal-title":"Abdom Radiol"},{"issue":"5","key":"2401_CR88","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","volume":"65","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006\u201316. https:\/\/doi.org\/10.1016\/j.jhep.2016.06.005.","journal-title":"J Hepatol"},{"issue":"11","key":"2401_CR89","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1016\/j.acra.2025.03.008","volume":"32","author":"S Wu","year":"2025","unstructured":"Wu S, Pan J, Song M, et al. Performance of magnetic resonance imaging and ultrasound for identifying the different degrees of hepatic steatosis: A systematic review and meta-analysis. Acad Radiol. 2025;32(11):6528\u20136540. https:\/\/doi.org\/10.1016\/j.acra.2025.03.008.","journal-title":"Acad Radiol Preprint posted online"},{"issue":"4","key":"2401_CR90","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10396-020-01059-x","volume":"47","author":"K Imajo","year":"2020","unstructured":"Imajo K, Honda Y, Yoneda M, Saito S, Nakajima A. Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. J Med Ultrasonics. 2020;47(4):535\u201348. https:\/\/doi.org\/10.1007\/s10396-020-01059-x.","journal-title":"J Med Ultrasonics"},{"issue":"4","key":"2401_CR91","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","volume":"17","author":"C Hsu","year":"2019","unstructured":"Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17(4):630\u20137.e8. https:\/\/doi.org\/10.1016\/j.cgh.2018.05.059.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2401_CR92","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.29302","volume":"66","author":"G Xiao","year":"2017","unstructured":"Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486\u2013501. https:\/\/doi.org\/10.1002\/hep.29302.","journal-title":"Hepatology"},{"issue":"12","key":"2401_CR93","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/apt.17995","volume":"59","author":"T Tsutsumi","year":"2024","unstructured":"Tsutsumi T, Kawaguchi T, Fujii H, et al. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: a multicenter study in Japan. Aliment Pharmacol Ther. 2024;59(12):1559\u201370. https:\/\/doi.org\/10.1111\/apt.17995.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2401_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):00980-1. https:\/\/doi.org\/10.1186\/s12902-022-00980-1.","journal-title":"BMC Endocr Disord"},{"key":"2401_CR95","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29:2919\u201328. https:\/\/doi.org\/10.1038\/s41591-023-02603-1.","journal-title":"Nat Med"},{"issue":"3","key":"2401_CR96","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL\u2013EASD\u2013EASO","year":"2024","unstructured":"EASL\u2013EASD\u2013EASO. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"key":"2401_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.hnm.2022.200150","volume":"28","author":"H Sugiyama","year":"2022","unstructured":"Sugiyama H, Kobayashi Y, Wada S, et al. An examination of eating behavior in patients with non-alcoholic fatty liver disease: a cross-sectional study in a Japanese population. Hum Nutr Metab. 2022;28:200150. https:\/\/doi.org\/10.1016\/j.hnm.2022.200150.","journal-title":"Hum Nutr Metab"},{"issue":"12","key":"2401_CR98","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.3390\/nu15122764","volume":"15","author":"Y Yabe","year":"2023","unstructured":"Yabe Y, Chihara K, Oshida N, et al. Survey of dietary habits and physical activity in japanese patients with non-obese non-alcoholic fatty liver disease. Nutrients. 2023;15(12):2764. https:\/\/doi.org\/10.3390\/nu15122764.","journal-title":"Nutrients"},{"issue":"6","key":"2401_CR99","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2169\/internalmedicine.1715-23","volume":"63","author":"A Sato","year":"2024","unstructured":"Sato A, Oomori Y, Nakano R, Matsuura T. Nonalcoholic fatty liver disease in Japan continue to increase even after the launch of specific health checkups. Intern Med Tokyo. 2024;63(6):763\u201371. https:\/\/doi.org\/10.2169\/internalmedicine.1715-23.","journal-title":"Intern Med Tokyo"},{"key":"2401_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/nu15051175","volume":"15","author":"Y Matsumoto","year":"2023","unstructured":"Matsumoto Y, Fujii H, Harima M, et al. Severity of liver fibrosis is associated with the Japanese diet pattern and skeletal muscle mass in patients with nonalcoholic fatty liver disease. Nutrients. 2023;15:1175. https:\/\/doi.org\/10.3390\/nu15051175.","journal-title":"Nutrients"},{"key":"2401_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/nu16172877","volume":"16","author":"T Sasada","year":"2024","unstructured":"Sasada T, Iino C, Sato S, Tateda T, et al. The impact of Japanese dietary patterns on metabolic dysfunction-associated steatotic liver disease and liver fibrosis. Nutrients. 2024;16:2877. https:\/\/doi.org\/10.3390\/nu16172877.","journal-title":"Nutrients"},{"issue":"12","key":"2401_CR102","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/hepr.13954","volume":"53","author":"H Tamai","year":"2023","unstructured":"Tamai H, Okamura J, Nanjo K. Moderate-carbohydrate diet without caloric or lipid restriction for Japanese adult patients with nonalcoholic fatty liver disease: a prospective cohort study. Hepatol Res. 2023;53(12):1185\u201397. https:\/\/doi.org\/10.1111\/hepr.13954.","journal-title":"Hepatol Res"},{"issue":"7","key":"2401_CR103","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/hepr.13897","volume":"53","author":"N Akuta","year":"2023","unstructured":"Akuta N, Kawamura Y, Fujiyama S, et al. Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors. Hepatol Res. 2023;53(7):607\u201317. https:\/\/doi.org\/10.1111\/hepr.13897.","journal-title":"Hepatol Res"},{"issue":"3","key":"2401_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100253","volume":"3","author":"S Oh","year":"2021","unstructured":"Oh S, Tsujimoto T, Kim B, et al. Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD. JHEP Reports. 2021;3(3):100253. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100253.","journal-title":"JHEP Reports"},{"issue":"3","key":"2401_CR105","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3164\/jcbn.17-115","volume":"62","author":"T Osaka","year":"2018","unstructured":"Osaka T, Hashimoto Y, Hamaguchi M, Kojima T, Obora A, Fukui M. Nonalcoholic fatty liver disease remission in men through regular exercise. J Clin Biochem Nutr. 2018;62(3):242\u20136. https:\/\/doi.org\/10.3164\/jcbn.17-115.","journal-title":"J Clin Biochem Nutr"},{"issue":"3","key":"2401_CR106","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jgh3.12876","volume":"7","author":"R Hashida","year":"2023","unstructured":"Hashida R, Nakano D, Matsuse H, et al. A low-intensity 10-min resistance exercise program that ameliorated hepatic fibrosis indices and altered G-CSF\/IP-10\/PDGF-BB in a patient with nonalcoholic fatty liver disease: a case report. JGH Open. 2023;7(3):231\u20134. https:\/\/doi.org\/10.1002\/jgh3.12876.","journal-title":"JGH Open"},{"key":"2401_CR107","unstructured":"Japan Society of Hepatology. Significance of exercise therapy for fatty liver. NAFLD\/NASH Guidelines. [Internet]. [cited 2026 Feb 4]. https:\/\/www.jsh.or.jp\/medical\/committeeactivity\/shakaihoken\/fatty.html. Accessed February 4, 2026."},{"issue":"3","key":"2401_CR108","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/hepr.70132","volume":"56","author":"S Terai","year":"2026","unstructured":"Terai S, Kamimura H, Hiasa Y, et al. Guidance for liver rehabilitation in chronic liver disease. Hepatol Res. 2026. https:\/\/doi.org\/10.1111\/hepr.70132.","journal-title":"Hepatol Res"},{"issue":"6","key":"2401_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21061907","volume":"21","author":"Y Sumida","year":"2020","unstructured":"Sumida Y, Yoneda M, Tokushige K, et al. Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Int J Mol Sci. 2020;21(6):1907. https:\/\/doi.org\/10.3390\/ijms21061907.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2401_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040901","volume":"10","author":"A Umemura","year":"2022","unstructured":"Umemura A, Kataoka S, Okuda K, et al. Potential therapeutic targets and promising agents for combating NAFLD. Biomedicines. 2022;10(4):0901. https:\/\/doi.org\/10.3390\/biomedicines10040901.","journal-title":"Biomedicines"},{"key":"2401_CR111","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1111\/dom.15898","volume":"26","author":"T Arai","year":"2024","unstructured":"Arai T, Atsukawa M, Tsubota A, et al. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction\u2010associated steatotic liver disease: a prospective, multicentre, observational study. Diabetes Obes Metab. 2024;26:4958\u201365. https:\/\/doi.org\/10.1111\/dom.15898.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2401_CR112","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/apt.17709","volume":"58","author":"N Alkhouri","year":"2023","unstructured":"Alkhouri N, Lazas D, Loomba R, et al. Clinical trial: effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2023;58(10):1005\u201315. https:\/\/doi.org\/10.1111\/apt.17709.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2401_CR113","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","volume":"79","author":"M Romero-G\u00f3mez","year":"2023","unstructured":"Romero-G\u00f3mez M, Lawitz E, Shankar RR, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023;79(4):888\u201397. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.013.","journal-title":"J Hepatol"},{"issue":"4","key":"2401_CR114","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/nejmoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/nejmoa2401943.","journal-title":"N Engl J Med"},{"issue":"4","key":"2401_CR115","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2401755.","journal-title":"N Engl J Med"},{"issue":"11","key":"2401_CR116","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1002\/hep4.2069","volume":"6","author":"T Arai","year":"2022","unstructured":"Arai T, Atsukawa M, Tsubota A, et al. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun. 2022;6(11):3073\u201382. https:\/\/doi.org\/10.1002\/hep4.2069.","journal-title":"Hepatol Commun"},{"key":"2401_CR117","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735. https:\/\/doi.org\/10.1136\/bmj-2024-083735.","journal-title":"BMJ"},{"issue":"2","key":"2401_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020428","volume":"14","author":"E Michalopoulou","year":"2025","unstructured":"Michalopoulou E, Thymis J, Lampsas S, et al. The triad of risk: linking MASLD, cardiovascular disease and type 2 diabetes; from pathophysiology to treatment. J Clin Med. 2025;14(2):428. https:\/\/doi.org\/10.3390\/jcm14020428.","journal-title":"J Clin Med"},{"issue":"2","key":"2401_CR119","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Lawitz EJ, Frias JP, et al. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol. 2023;8(2):120\u201332. https:\/\/doi.org\/10.1016\/S2468-1253(22)00347-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"2401_CR120","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/nejmoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389(11):998\u20131008. https:\/\/doi.org\/10.1056\/nejmoa2304286.","journal-title":"N Engl J Med"},{"issue":"7","key":"2401_CR121","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Ruane PJ, Freilich BL, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med. 2021;27(7):1262\u201371. https:\/\/doi.org\/10.1038\/s41591-021-01425-3.","journal-title":"Nat Med"},{"issue":"6","key":"2401_CR122","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","volume":"82","author":"D Barb","year":"2025","unstructured":"Barb D, Kalavalapalli S, Godinez Leiva E, et al. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. J Hepatol. 2025;82(6):979\u201391. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.045.","journal-title":"J Hepatol"},{"issue":"17","key":"2401_CR123","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/nejmoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385(17):1547\u201358. https:\/\/doi.org\/10.1056\/nejmoa2036205.","journal-title":"N Engl J Med"},{"issue":"10","key":"2401_CR124","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/apt.16596","volume":"54","author":"A Nakajima","year":"2021","unstructured":"Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator\u2010activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non\u2010alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54(10):1263\u201377. https:\/\/doi.org\/10.1111\/apt.16596.","journal-title":"Aliment Pharmacol Ther"},{"key":"2401_CR125","doi-asserted-by":"publisher","DOI":"10.5551\/jat.64896","volume":"31","author":"Y Sumida","year":"2024","unstructured":"Sumida Y, Toyoda H, Yasuda S, et al. Comparison of efficacy between pemafibrate and omega-3-acid ethyl ester in the liver: the PORTRAIT study. J Atheroscler Thromb. 2024;31:64896. https:\/\/doi.org\/10.5551\/jat.64896.","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"2401_CR126","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.jhep.2023.02.004","volume":"78","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Thang C, Bolze S, et al. Evaluation of PXL065\u2014deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1). J Hepatol. 2023;78(5):914\u201325. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.004.","journal-title":"J Hepatol"},{"issue":"10213","key":"2401_CR127","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(19)32517-6.","journal-title":"Lancet"},{"issue":"26","key":"2401_CR128","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033981","volume":"102","author":"H Zhou","year":"2023","unstructured":"Zhou H, Toshiyoshi M, Zhao W, Zhao Y, Zhao Y. Statins on nonalcoholic fatty liver disease: a systematic review and meta-analysis of 14 RCTs. Medicine. 2023;102(26):E33981. https:\/\/doi.org\/10.1097\/MD.0000000000033981.","journal-title":"Medicine"},{"issue":"6","key":"2401_CR129","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1177\/10600280221126971","volume":"57","author":"C Nakagawa","year":"2023","unstructured":"Nakagawa C, Yokoyama S, Hosomi K. Association of statin adherence with the development of nonalcoholic fatty liver disease: a nested case-control study using a Japanese claims database. Ann Pharmacother. 2023;57(6):637\u201345. https:\/\/doi.org\/10.1177\/10600280221126971.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2401_CR130","doi-asserted-by":"publisher","first-page":"e70036","DOI":"10.1111\/liv.70036","volume":"45","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Mayo P, Hobbs T, et al. Rencofilstat treatment improves liver function in MASH with advanced fibrosis as quantified by HepQuant DuO. Liver Int. 2025;45(3):e70036. https:\/\/doi.org\/10.1111\/liv.70036.","journal-title":"Liver Int"},{"issue":"4","key":"2401_CR131","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","volume":"78","author":"QM Anstee","year":"2023","unstructured":"Anstee QM, Lucas KJ, Francque S, et al. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: results from the phase 2b TANDEM study. Hepatol. 2023;78(4):1223\u201339. https:\/\/doi.org\/10.1097\/HEP.0000000000000439.","journal-title":"Hepatol"},{"issue":"3","key":"2401_CR132","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/hep.31108","volume":"72","author":"V Ratziu","year":"2020","unstructured":"Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatol. 2020;72(3):892\u2013905. https:\/\/doi.org\/10.1002\/hep.31108.","journal-title":"Hepatol"},{"key":"2401_CR133","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","volume":"47","author":"S Friedman","year":"2016","unstructured":"Friedman S, Sanyal A, Goodman Z, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR phase 2b study design. Contemp Clin Trials. 2016;47:356\u201365. https:\/\/doi.org\/10.1016\/j.cct.2016.02.012.","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"2401_CR134","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40264-024-01436-2","volume":"47","author":"A Mor","year":"2024","unstructured":"Mor A, Friedman S, Hashmueli S, et al. Targeting CCL24 in inflammatory and fibrotic diseases: rationale and results from three CM-101 phase 1 studies. Drug Saf. 2024;47(9):869\u201381. https:\/\/doi.org\/10.1007\/s40264-024-01436-2.","journal-title":"Drug Saf"},{"issue":"11","key":"2401_CR135","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1001\/jama.2024.1215","volume":"331","author":"TG Simon","year":"2024","unstructured":"Simon TG, Wilechansky RM, Stoyanova S, et al. Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial. JAMA. 2024;331(11):920\u20139. https:\/\/doi.org\/10.1001\/jama.2024.1215.","journal-title":"JAMA"},{"issue":"3","key":"2401_CR136","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00535-021-01759-2","volume":"56","author":"S Terai","year":"2021","unstructured":"Terai S, Buchanan-Hughes A, Ng A, Lee IH, Hasegawa K. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database. J Gastroenterol. 2021;56(3):274\u201384. https:\/\/doi.org\/10.1007\/s00535-021-01759-2.","journal-title":"J Gastroenterol"},{"issue":"11","key":"2401_CR137","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3390\/life13112144","volume":"13","author":"K Nagai","year":"2023","unstructured":"Nagai K, Nagai K, Iwaki M, et al. Frontiers of collaboration between primary care and specialists in the management of metabolic dysfunction-associated steatotic liver disease: a review. Life. 2023;13(11):2144. https:\/\/doi.org\/10.3390\/life13112144.","journal-title":"Life"},{"issue":"2","key":"2401_CR138","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00535-022-01932-1","volume":"58","author":"Y Kamada","year":"2023","unstructured":"Kamada Y, Nakamura T, Isobe S, et al. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. J Gastroenterol. 2023;58(2):79\u201397. https:\/\/doi.org\/10.1007\/s00535-022-01932-1.","journal-title":"J Gastroenterol"},{"issue":"6","key":"2401_CR139","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1002\/hep.32081","volume":"74","author":"S Kumar","year":"2021","unstructured":"Kumar S, Wong R, Newberry C, Yeung M, Pe\u00f1a JM, Sharaiha RZ. Multidisciplinary clinic models: a paradigm of care for management of NAFLD. Hepatol. 2021;74(6):3472\u20138. https:\/\/doi.org\/10.1002\/hep.32081.","journal-title":"Hepatol"},{"issue":"4","key":"2401_CR140","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/flgastro-2018-101155","volume":"10","author":"A Moolla","year":"2019","unstructured":"Moolla A, Motohashi K, Marjot T, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 2019;10(4):337\u201346. https:\/\/doi.org\/10.1136\/flgastro-2018-101155.","journal-title":"Frontline Gastroenterol"},{"key":"2401_CR141","doi-asserted-by":"publisher","first-page":"843","DOI":"10.5009\/gnl220545","volume":"17","author":"M Yoneda","year":"2023","unstructured":"Yoneda M, Kobayashi T, Iwaki M, Nogami A, Saito S, Nakajima A. Nonalcoholic fatty liver disease as a systemic disease and the need for multidisciplinary care. Gut Liver. 2023;17:843\u201352. https:\/\/doi.org\/10.5009\/gnl220545.","journal-title":"Gut Liver"},{"issue":"2","key":"2401_CR142","doi-asserted-by":"publisher","first-page":"101789","DOI":"10.1016\/j.aohep.2025.101789","volume":"30","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Paik JM, Henry L, Pollock RF, Stepanova M, Nader F. Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK). Ann Hepatol. 2025;30(2):101789. https:\/\/doi.org\/10.1016\/j.aohep.2025.101789.","journal-title":"Ann Hepatol"},{"issue":"4","key":"2401_CR143","doi-asserted-by":"publisher","first-page":"e16119","DOI":"10.1111\/liv.16119","volume":"45","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Paik JM, Henry L, Stepanova M, Nader F. Pharmaco\u2010economic assessment of screening strategies for high\u2010risk MASLD in primary care. Liver Int. 2025;45(4):e16119. https:\/\/doi.org\/10.1111\/liv.16119.","journal-title":"Liver Int"},{"issue":"1","key":"2401_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2185\/jrm.2023-026","volume":"19","author":"K Shibayama","year":"2024","unstructured":"Shibayama K, Furushima C, Saka M, Sakamoto T, Takahashi H. Barriers to lifestyle modification in patients with non-alcoholic fatty liver disease: a scoping review. J Rural Med. 2024;19(1):1\u20139. https:\/\/doi.org\/10.2185\/jrm.2023-026.","journal-title":"J Rural Med"},{"key":"2401_CR145","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","volume":"66","author":"R Hashida","year":"2017","unstructured":"Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol. 2017;66:142\u201352. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.023.","journal-title":"J Hepatol"},{"key":"2401_CR146","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/197216","author":"E Yoshimura","year":"2014","unstructured":"Yoshimura E, Kumahara H, Tobina T, et al. Lifestyle intervention involving calorie restriction with or without aerobic exercise training improves liver fat in adults with visceral adiposity. J Obes. 2014. https:\/\/doi.org\/10.1155\/2014\/197216.","journal-title":"J Obes"},{"key":"2401_CR147","unstructured":"Novo Nordisk Q1 investor presentation [Internet]. 2025. https:\/\/www.novonordisk.com\/content\/dam\/nncorp\/global\/en\/investors\/pdfs\/financial-results\/2025\/Q1-2025-investor-presentation.pdf. Accessed February 17, 2026."},{"issue":"2","key":"2401_CR148","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3892\/etm.2020.8798","volume":"20","author":"Y Tsuji","year":"2020","unstructured":"Tsuji Y, Namisaki T, Kaji K, et al. Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic Hepatitis B. Exp Ther Med. 2020;20(2):985\u201395. https:\/\/doi.org\/10.3892\/etm.2020.8798.","journal-title":"Exp Ther Med"},{"issue":"1","key":"2401_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25843-6","volume":"12","author":"A Nogami","year":"2022","unstructured":"Nogami A, Yoneda M, Iwaki M, et al. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD. Sci Rep. 2022;12(1):21925. https:\/\/doi.org\/10.1038\/s41598-022-25843-6.","journal-title":"Sci Rep"},{"issue":"1","key":"2401_CR150","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10396-024-01473-5","volume":"52","author":"T Kobayashi","year":"2025","unstructured":"Kobayashi T, Nakatsuka T, Sato M, et al. Diagnostic performance of two-dimensional shear wave elastography and attenuation imaging for fibrosis and steatosis assessment in chronic liver disease. J Med Ultrason. 2025;52(1):95\u2013103. https:\/\/doi.org\/10.1007\/s10396-024-01473-5.","journal-title":"J Med Ultrason"},{"issue":"1","key":"2401_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-12-2","volume":"12","author":"Y Sumida","year":"2012","unstructured":"Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12(1):2. https:\/\/doi.org\/10.1186\/1471-230X-12-2.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"2401_CR152","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147\u201359.e5. https:\/\/doi.org\/10.1053\/j.gastro.2016.01.038.","journal-title":"Gastroenterology"},{"issue":"7","key":"2401_CR153","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","volume":"7","author":"SA Harrison","year":"2022","unstructured":"Harrison SA, Abdelmalek MF, Neff G, et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022;7(7):603\u201316. https:\/\/doi.org\/10.1016\/S2468-1253(22)00017-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2401_CR154","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056159","volume":"12","author":"NB Amin","year":"2022","unstructured":"Amin NB, Darekar A, Anstee QM, et al. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. BMJ Open. 2022;12(3):e056159. https:\/\/doi.org\/10.1136\/bmjopen-2021-056159.","journal-title":"BMJ Open"},{"issue":"3","key":"2401_CR155","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00280-023-04513-y","volume":"91","author":"V Aslanis","year":"2023","unstructured":"Aslanis V, Slack RJ, MacKinnon AC, et al. Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer Chemother Pharmacol. 2023;91(3):267\u201380. https:\/\/doi.org\/10.1007\/s00280-023-04513-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"2401_CR156","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2337\/dc17-0374","volume":"40","author":"CRL Cardoso","year":"2017","unstructured":"Cardoso CRL, Leite NC, Carlos FO, Loureiro A, Viegas BB, Salles GF. Efficacy and safety of diacerein in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Care. 2017;40(10):1356\u201363. https:\/\/doi.org\/10.2337\/dc17-0374.","journal-title":"Diabetes Care"},{"issue":"11","key":"2401_CR157","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/liv.14209","volume":"39","author":"PJ Pockros","year":"2019","unstructured":"Pockros PJ, Fuchs M, Freilich B, et al. CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int. 2019;39(11):2082\u201393. https:\/\/doi.org\/10.1111\/liv.14209.","journal-title":"Liver Int"},{"issue":"10","key":"2401_CR158","doi-asserted-by":"publisher","first-page":"e10459","DOI":"10.15252\/msb.202110459","volume":"17","author":"M Zeybel","year":"2021","unstructured":"Zeybel M, Altay O, Arif M, et al. Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients. Mol Syst Biol. 2021;17(10):e10459. https:\/\/doi.org\/10.15252\/msb.202110459.","journal-title":"Mol Syst Biol"},{"issue":"9","key":"2401_CR159","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/LVT.0000000000000110","volume":"29","author":"MS Siddiqui","year":"2023","unstructured":"Siddiqui MS, Parmar D, Shaikh F, et al. Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients. Liver Transpl. 2023;29(9):979\u201386. https:\/\/doi.org\/10.1097\/LVT.0000000000000110.","journal-title":"Liver Transpl"},{"issue":"5","key":"2401_CR160","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S2213-8587(13)70170-0","volume":"2","author":"N Stefan","year":"2014","unstructured":"Stefan N, Ramsauer M, Jordan P, et al. Inhibition of 11\u03b2-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):406\u201316. https:\/\/doi.org\/10.1016\/S2213-8587(13)70170-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2401_CR161","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s13318-017-0429-7","volume":"43","author":"N Siebers","year":"2018","unstructured":"Siebers N, Palmer M, Silberg DG, Jennings L, Bliss C, Martin PT. Absorption, distribution, metabolism, and excretion of [14C]-volixibat in healthy men: phase 1 open-label study. Eur J Drug Metab Pharmacokinet. 2018;43(1):91\u2013101. https:\/\/doi.org\/10.1007\/s13318-017-0429-7.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2401_CR162","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"key":"2401_CR163","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02401-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02401-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02401-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:44:54Z","timestamp":1781948694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02401-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":163,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2401"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02401-9","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}